Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × INDUSTRY × urelumab × Clear all

Phase

Status

Completed 6 Terminated 3 Withdrawn 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Paclitaxel 26 Cyclophosphamide 25 Cisplatin 24 Carboplatin 22 Bevacizumab 20 Nivolumab 19 pembrolizumab 18 Docetaxel 18 Rituximab 17 Fluorouracil 17 Dexamethasone 15 avelumab 14 Leucovorin 13 Gemcitabine 13 Capecitabine 11 fludarabine 10 Ipilimumab 10 venetoclax 9 atezolizumab 9 Radiotherapy 9 Cetuximab 9 ALT-803 9 130-nm albumin-bound paclitaxel 9 Pemetrexed 8 trametinib 7 Radiosurgery 7 Prednisone 7 Oxaliplatin 7 Lenalidomide 7 Bendamustine Hydrochloride 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00803374 2011-11-21

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Bristol-Myers Squibb

Phase 1 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡